Together, our results suggested that the GUSBP5-AS/miR-223-3p/FOXO1 axis appears to play a crucial role in DVT progression and EPC angiogenesis, providing a novel biomarker and promising therapeutic target for DVT patients. This evidence concerns the gene GUSBP5 and deep vein thrombosis.